These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus. Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565 [TBL] [Abstract][Full Text] [Related]
48. What's new in columnar lined esophagus (Barrett's metaplasia)? Tadiparthi R; Bansal A; Sharma P Curr Opin Gastroenterol; 2008 Jul; 24(4):516-20. PubMed ID: 18622169 [TBL] [Abstract][Full Text] [Related]
49. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia. Anandasabapathy S; Jhamb J; Davila M; Wei C; Morris J; Bresalier R Cancer; 2007 Feb; 109(4):668-74. PubMed ID: 17211862 [TBL] [Abstract][Full Text] [Related]
50. Endoscopic therapy of dysplasia and early-stage cancers of the esophagus. Tokar JL; Haluszka O; Weinberg DS Semin Radiat Oncol; 2007 Jan; 17(1):10-21. PubMed ID: 17185193 [TBL] [Abstract][Full Text] [Related]
51. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Sharma P; Falk GW; Weston AP; Reker D; Johnston M; Sampliner RE Clin Gastroenterol Hepatol; 2006 May; 4(5):566-72. PubMed ID: 16630761 [TBL] [Abstract][Full Text] [Related]
52. Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus. Glickman JN; Blount PL; Sanchez CA; Cowan DS; Wongsurawat VJ; Reid BJ; Odze RD Hum Pathol; 2006 Oct; 37(10):1304-15. PubMed ID: 16949933 [TBL] [Abstract][Full Text] [Related]
53. Histology of metaplasia and dysplasia in Barrett's esophagus. Yerian L Surg Oncol Clin N Am; 2009 Jul; 18(3):411-22. PubMed ID: 19500733 [TBL] [Abstract][Full Text] [Related]
54. Duplication of the muscularis mucosae in Barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma. Abraham SC; Krasinskas AM; Correa AM; Hofstetter WL; Ajani JA; Swisher SG; Wu TT Am J Surg Pathol; 2007 Nov; 31(11):1719-25. PubMed ID: 18059229 [TBL] [Abstract][Full Text] [Related]
55. Low-grade dysplasia in Barrett's esophagus has a high risk of progression. Lim CH; Treanor D; Dixon MF; Axon AT Endoscopy; 2007 Jul; 39(7):581-7. PubMed ID: 17611911 [TBL] [Abstract][Full Text] [Related]
56. Future developments in total Barrett's eradication: the surgeon's view. Watson TJ; Peters JH Endoscopy; 2008 Dec; 40(12):1048-51. PubMed ID: 19065490 [TBL] [Abstract][Full Text] [Related]
57. Neoplastic precursor lesions in Barrett's esophagus. Hornick JL; Odze RD Gastroenterol Clin North Am; 2007 Dec; 36(4):775-96, v. PubMed ID: 17996790 [TBL] [Abstract][Full Text] [Related]
58. Histopathologic evaluation of an animal model for Barrett's esophagus and adenocarcinoma of the distal esophagus. Buskens CJ; Hulscher JB; van Gulik TM; Ten Kate FJ; van Lanschot JJ J Surg Res; 2006 Oct; 135(2):337-44. PubMed ID: 16926029 [TBL] [Abstract][Full Text] [Related]